sulfabenzamide; 127-71-9; N-Sulfanilylbenzamide; Sulfabenzide; Sulfabenzoylamide; Sulfabenzid; N-Benzoylsulfanilamide; N-Sulfamylbenzamide; N-(4-aminophenyl)sulfonylbenzamide; Sulfamylbenzamide; Sulfabenzamid; Sulfabenzamida; Sulfabenzamidum; Benzamide, N-[(4-aminophenyl)sulfonyl]-; Sultrin; N-(4-Aminobenzenesulfonyl)benzamide; N-[(4-Aminophenyl)sulfonyl]benzamide; N-(p-Aminobenzenesulfonyl)benzamide; N-((4-Aminophenyl)sulfonyl)benzamide; Benzamide, N-sulfanilyl-; N(sup1)-Benzoylsulfanilamide; Sulfanilamide, N(sup1)-benzoyl-; Benzamide, N-((4-aminophenyl)sulfonyl)-; NSC 74587; NSC-74587; G58F8OPL4I; Triple sulfa (sulfabenzamide); MLS000069716; DTXSID7045287; N-(4-aminophenylsulfonyl)benzamide; NSC74587; NCGC00016385-01; CAS-127-71-9; SMR000058257; Sulfabenzamide(SB); DTXCID5025287; n-((4-aminophenyl)sulfonyl)-benzamid; Sulfabenzamidum [INN-Latin]; Sulfabenzamida [INN-Spanish]; N(sup 1)-Benzoylsulfanilamide; N1-Benzoylsulfanilamide; Sulfanilamide, N(sup 1)-benzoyl-; SR-01000000178; EINECS 204-859-4; UNII-G58F8OPL4I; BRN 2139003; Sulphabenzamide; AI3-08024; MFCD00044890; Prestwick_1019; Sulfabenzamide [USAN:USP:INN:BAN]; Sulphabenzamide, USP; Spectrum_000982; Opera_ID_1271; Prestwick0_000711; Prestwick1_000711; Prestwick2_000711; Prestwick3_000711; Spectrum2_001317; Spectrum3_000569; Spectrum4_000341; Spectrum5_001066; N(1)-benzoylsulfanilamide; Sulfabenzamide (USP/INN); SULFABENZAMIDE [MI]; BENZOYL SULFANILAMIDE; Sulfanilamide, N1-benzoyl-; CHEMBL1243; SULFABENZAMIDE [INN]; SCHEMBL93841; BSPBio_000921; BSPBio_001958; KBioGR_000741; KBioSS_001462; SULFABENZAMIDE [USAN]; 4-14-00-02664 (Beilstein Handbook Reference); DivK1c_000537; SPECTRUM1500544; SULFABENZAMIDE [VANDF]; SPBio_001413; SPBio_002842; SULFABENZAMIDE [MART.]; BPBio1_001015; SULFABENZAMIDE [USP-RS]; SULFABENZAMIDE [WHO-DD]; CHEBI:94677; HMS501K19; KBio1_000537; KBio2_001462; KBio2_004030; KBio2_006598; KBio3_001458; N-benzoyl4-aminobenzenesulfonamide; NINDS_000537; HMS1570O03; HMS1921A09; HMS2092I11; HMS2097O03; HMS2234F05; HMS3372C11; HMS3714O03; Pharmakon1600-01500544; 4-Amino-N-benzoylbenzenesulfonamide; N-benzoyl-4-aminobenzenesulfonamide; AMY37036; HY-B0960; ZINC5421253; SULFABENZAMIDE [ORANGE BOOK]; Tox21_110410; CCG-39255; NSC757322; s4576; STK985629; SULFABENZAMIDE (TRIPLE SULFA); SULFABENZAMIDE [USP IMPURITY]; TRYSUL COMPONENT SULFABENZAMIDE; 4-Amino-N-benzoylbenzenesulfonamide #; AKOS000482643; SULTRIN COMPONENT SULFABENZAMIDE; Tox21_110410_1; VAGILIA COMPONENT SULFABENZAMIDE; BS-4997; CS-4442; DB09355; N-[(4-aminophenyl)sulfonyl]-benzamide; NSC-757322; IDI1_000537; N-(4-aminobenzene-1-sulfonyl)benzamide; GYNE-SULF COMPONENT SULFABENZAMIDE; NCGC00016385-02; NCGC00016385-03; NCGC00016385-04; NCGC00016385-05; NCGC00016385-06; NCGC00016385-08; NCGC00022347-03; NCGC00022347-04; SULFABENZAMIDE COMPONENT OF TRYSUL; AC-24189; SULFABENZAMIDE COMPONENT OF SULTRIN; SULFABENZAMIDE COMPONENT OF VAGILIA; SBI-0051518.P003; DB-041871; AB00052093; FT-0631744; S0582; SULFABENZAMIDE COMPONENT OF GYNE-SULF; C72147; D05946; AB00052093_15; EN300-7411279; 4-amino-N-(1-phenyl-methanoyl)-benzenesulfonamide; Sulfabenzamide, VETRANAL(TM), analytical standard; J-005533; Q7636176; SR-01000000178-2; SR-01000000178-3; TRIPLE SULFA (SULFABENZAMIDE) [ORANGE BOOK]; BRD-K59983611-001-05-2; BRD-K59983611-001-15-1; Sulfabenzamide, United States Pharmacopeia (USP) Reference Standard; BS4